Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

iShares 0 3 Month Treasury Bond ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

iShares 0 3 Month Treasury Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B), while Zimmer Biomet Holdings Inc trades at $88.75 (market cap $16.95B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 6.7× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 50 Days and Zimmer Biomet Holdings Inc for 89 Days on average.

SGOVZBH
Market Cap
$114.40B$16.95B
Volume
18,879,0812,505,240
Sector
Fixed IncomeHealth
52-Week High
$100.72$103.98
52-Week Low
$100.28$79.58
Typical Hold Time
50 Days89 Days
Enterprise Value
—$24.02B
Dividend Yield
—1.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 0 3 Month Treasury Bond ETF

SGOV trades at $100.51 with minimal daily movement (+0.04%), reflecting its stable Treasury bond ETF nature. Technical indicators show bearish momentum with oversold RSI readings, while fundamental data remains limited for this short-term Treasury fund. Recent institutional selling by Envestnet Asset Management indicates some professional caution, though the fund continues regular dividend distributions.

The outlook remains stable given SGOV's short-term Treasury focus, though rising bond yields present both opportunity and risk. Investors benefit from monthly dividends but face interest rate sensitivity. Current technical weakness suggests potential near-term pressure despite the fund's defensive characteristics in volatile markets.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SGOV
90% Buy10% Sell
Avg holding period · 50 Days
ZBH
100% Buy0% Sell
Avg holding period · 89 Days

Top news

Latest headlines on both assets

About iShares 0 3 Month Treasury Bond ETF

SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.

Read more on SGOV →

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH →